Three million members of CVS Caremarks clients now enjoy access to clinical weight loss program with proven results, high satisfaction WOONSOCKET, R.I., March 14, 2025 CVS Health (NYSE: CVS) released compelling data today from the CVS Weight Management TM program in which participants achieved more than 15% weight loss on average, including existing anti-obesity medication users who succeeded in nearly doubling their pre-program weight loss while working with program clinicians on diet and lifestyle.* Before enrolling in the CVS Weight Management program, 70% of members were using a weight management drug without any lifestyle or nutrition support.* The initial results demonstrate improved weight loss and high program satisfaction for CVS Caremark clients' plan members trying a lifestyle-first approach and additional clinical effectiveness and cost savings for members receiving clinical support while taking weight management medications like GLP-1s
Semaglutide (a GLP-1R monoagonist) achieved mean weight reductions of approximately 1517% in the STEP clinical trial programme (STEP-1, NEJM 2021)
Secoisolariciresinol diglucoside of flaxseed and its metabolites: biosynthesis and potential for nutraceuticals
Cerebrospinal fluid metabolite alterations in patients with different etiologies, diagnoses, and prognoses of disorders of consciousness
Ingredients ingredients Water, L-carnitine (9.2 ), fructose, acidic agent (citronic acid), zinc citrate, acid regulator (sodium hydroxide), preserving ff (potassium sorbate), sweetener (cyclamat, acesulfam k, saccharin), aroma
